Nature Biotechnology (NAT BIOTECHNOL )
The journal publishes novel biological research with significant commercial potential in the pharmaceutical, medical, agricultural, and environmental sciences - research that takes biology out of the laboratory and into the marketplace.
- Impact factor32.44Show impact factor historyHide impact factor history
- 5-year impact32.18
- Cited half-life6.80
- Immediacy index7.09
- Article influence14.93
- WebsiteNature Biotechnology website
- Other titlesNature biotechnology, Bioentrepreneur
- Material typePeriodical, Internet resource
- Document typeJournal / Magazine / Newspaper, Internet Resource
- Author can archive a pre-print version
- Author cannot archive a post-print version
- 6 months embargo
- Published source must be acknowledged and DOI cited
- Must link to publisher version
- Publisher's version/PDF cannot be used
- On funding body's archive, author website and institutional repository
- If funding agency rules apply, authors may post authors version to their relevant funding body's archive, 6 months after publication
- Several Journals have paid open access options and licenses (see journal homepages)
- Creative Commons Licenses available for selected titles.
- Classification yellow
Publications in this journal
- [Show abstract] [Hide abstract]
ABSTRACT: The concordance of RNA-sequencing (RNA-seq) with microarrays for genome-wide analysis of differential gene expression has not been rigorously assessed using a range of chemical treatment conditions. Here we use a comprehensive study design to generate Illumina RNA-seq and Affymetrix microarray data from the same liver samples of rats exposed in triplicate to varying degrees of perturbation by 27 chemicals representing multiple modes of action (MOAs). The cross-platform concordance in terms of differentially expressed genes (DEGs) or enriched pathways is linearly correlated with treatment effect size (R2≈0.8). Furthermore, the concordance is also affected by transcript abundance and biological complexity of the MOA. RNA-seq outperforms microarray (93% versus 75%) in DEG verification as assessed by quantitative PCR, with the gain mainly due to its improved accuracy for low-abundance transcripts. Nonetheless, classifiers to predict MOAs perform similarly when developed using data from either platform. Therefore, the endpoint studied and its biological complexity, transcript abundance and the genomic application are important factors in transcriptomic research and for clinical and regulatory decision making.Nature Biotechnology 08/2014;
Article: High-resolution metagenomics.Nature Biotechnology 08/2014; 32(8):750-751.
- Nature Biotechnology 08/2014; 32(8):754.
Article: The slippery slope of cisgenesis.Nature Biotechnology 08/2014; 32(8):727.
- Nature Biotechnology 08/2014; 32(8):703-704.
- Nature Biotechnology 08/2014; 32(8):705.
- Nature Biotechnology 08/2014; 32(8):708.
- Nature Biotechnology 08/2014; 32(8):706.
Article: Between disease and a dish.Nature Biotechnology 08/2014;
- [Show abstract] [Hide abstract]
ABSTRACT: Regenerative therapies that use allogeneic cells are likely to encounter immunological barriers similar to those that occur with transplantation of solid organs and allogeneic hematopoietic stem cells (HSCs). Decades of experience in clinical transplantation hold valuable lessons for regenerative medicine, offering approaches for developing tolerance-induction treatments relevant to cell therapies. Outside the field of solid-organ and allogeneic HSC transplantation, new strategies are emerging for controlling the immune response, such as methods based on biomaterials or mimicry of antigen-specific peripheral tolerance. Novel biomaterials can alter the behavior of cells in tissue-engineered constructs and can blunt host immune responses to cells and biomaterial scaffolds. Approaches to suppress autoreactive immune cells may also be useful in regenerative medicine. The most innovative solutions will be developed through closer collaboration among stem cell biologists, transplantation immunologists and materials scientists.Nature Biotechnology 08/2014;
- Nature Biotechnology 07/2014; 32(7):599-601.
- Nature Biotechnology 07/2014; 32(7):609.
- Nature Biotechnology 07/2014; 32(7):607.
- Nature Biotechnology 07/2014; 32(7):642-643.
- Nature Biotechnology 07/2014; 32(7):608.
Article: Beating the heat.Nature Biotechnology 07/2014; 32(7):610-613.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.
Association for Laboratory...
ISSN: 2211-0682, Impact factor: 1.46
ISSN: 2045-7758, Impact factor: 1.66
ISSN: 2045-2322, Impact factor: 5.08
ISSN: 1940-6029, Impact factor: 1.29
ISSN: 1872-6283, Impact factor: 2.1
ISSN: 1865-1682, Impact factor: 2.1
British Society of Animal Science;...
ISSN: 1751-732X, Impact factor: 1.65